Last 7 days
6.0%
Last 30 days
-2.3%
Last 90 days
-31.2%
Trailing 12 Months
-39.3%
Name | Mkt Capsorted ascending | Revenue | Price %, 1M | Returns, 1Y | P/E | P/S | Rev 1-Yr | Inc 1-Yr |
---|---|---|---|---|---|---|---|---|
LARGE-CAP | ||||||||
JNJ | 409.0B | 96.3B | -3.62% | -9.57% | 32.14 | 4.25 | 1.46% | -35.83% |
LLY | 398.5B | 27.7B | 2.58% | 47.15% | 70.08 | 14.39 | -5.56% | -7.22% |
MRK | 272.8B | 57.9B | -4.82% | 28.79% | 17.88 | 4.63 | 7.21% | -8.11% |
PFE | 230.9B | 93.0B | -0.23% | -25.99% | 7.36 | 2.3 | 0.56% | 16.36% |
BMY | 150.1B | 45.8B | -1.47% | -11.26% | 23.72 | 3.25 | -2.37% | 16.96% |
MID-CAP | ||||||||
PRGO | 5.0B | 4.6B | -12.00% | -16.92% | -35.25 | 1.11 | 8.46% | -29.07% |
RETA | 3.5B | 1.5M | -8.84% | 225.36% | -11.32 | 1.6K | -86.94% | -16.59% |
SMALL-CAP | ||||||||
SUPN | 1.8B | 668.5M | -9.91% | 19.28% | 34.95 | 2.72 | 11.17% | -29.04% |
TLRY | 1.6B | 596.3M | -7.75% | -62.41% | -0.89 | 2.66 | -3.41% | -3791.67% |
INVA | 866.9M | 271.5M | 14.22% | -13.24% | 3.94 | 3.19 | -31.50% | -40.28% |
CRON | 666.4M | 112.3M | -6.91% | -41.08% | -4.29 | 5.94 | 7.69% | 41.96% |
ACRS | 590.7M | 30.8M | -2.33% | -39.30% | -6.14 | 19.16 | 378.90% | -19.01% |
OCUL | 536.4M | 51.7M | 11.79% | 117.61% | -6.04 | 10.38 | 4.69% | -299.77% |
CGC | 401.1M | 478.9M | -31.81% | -82.48% | -0.13 | 0.84 | -31.50% | -634.70% |
ENDP | 94.1M | 2.2B | -43.99% | -88.43% | -0.03 | 0.04 | -25.47% | -292.77% |
Income Statement (Last 12 Months) | ||||||
---|---|---|---|---|---|---|
Description | (%) Q/Q | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 |
Revenue | 3.6% | 30,827,000 | 29,752,000 | 23,500,000 | 6,141,000 | 6,437,000 |
S&GA Expenses | 10.7% | 27,824,000 | 25,133,000 | 24,930,000 | 25,096,000 | 24,891,000 |
R&D Expenses | 10.6% | 86,094,000 | 77,813,000 | 70,843,000 | 61,163,000 | 50,281,000 |
EBITDA | 4.4% | -86,111,000 | -90,063,000 | -90,022,000 | - | - |
EBITDA Margin | 80.3% | -2.89 | -14.67 | -13.99 | - | - |
Earnings Before Taxes | - | -86,908,000 | - | - | - | - |
EBT Margin | 80.3% | -2.92 | -14.80 | -14.12 | - | - |
Net Income | -10.8% | -96,279,000 | -86,908,000 | -82,077,000 | -83,271,000 | -80,900,000 |
Net Income Margin | 16.4% | -2.92 | -3.49 | -13.56 | -12.57 | - |
Free Cahsflow | -2.9% | -68,172,000 | -66,227,000 | -68,922,000 | -61,431,000 | - |
Balance Sheet | (In Millions) | |||||
---|---|---|---|---|---|---|
Description | (%) Q/Q | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 |
Assets | -9.8% | 230 | 255 | 268 | 278 | 227 |
Current Assets | -20.4% | 184 | 232 | 257 | 259 | 191 |
Cash Equivalents | -1.2% | 45.00 | 45.00 | 62.00 | 68.00 | 36.00 |
Net PPE | 37.7% | 2.00 | 1.00 | 1.00 | 1.00 | 1.00 |
Liabilities | -7.2% | 53.00 | 57.00 | 48.00 | 42.00 | 46.00 |
Current Liabilities | -16.8% | 18.00 | 22.00 | 20.00 | 16.00 | 17.00 |
Shareholder's Equity | -10.5% | 177 | 198 | 220 | 236 | 180 |
Retained Earnings | -4.1% | -710 | -682 | -654 | -634 | -614 |
Additional Paid-In Capital | 0.8% | 888 | 881 | 876 | 872 | 795 |
Shares Outstanding | 0.8% | 67.00 | 67.00 | 67.00 | 67.00 | 62.00 |
Cashflow (Last 12 Months) | (In Thousands) | |||||
---|---|---|---|---|---|---|
Description | (%) Q/Q | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 |
Cashflow From Operations | -8.0% | -72,951 | -67,567 | -65,527 | -68,316 | -60,871 |
Share Based Compensation | 29.7% | 19,499 | 15,039 | 14,077 | 13,591 | 13,731 |
Cashflow From Investing | -32.7% | 8,494 | 12,628 | 750 | -38,139 | -62,386 |
Cashflow From Financing | 0.1% | 72,867 | 72,828 | 61,272 | 124,332 | - |
100%
100%
91.2%
Y-axis is the maximum loss one would have experienced if Aclaris Therapeutics was unfortunately bought at previous high price.
-11.2%
-13.6%
81.9%
FIve years rolling returns for Aclaris Therapeutics.
Datesorted ascending | Fund Name | Type | % Chg | $ Change | $ Held | % Portfolio |
---|---|---|---|---|---|---|
2023-05-26 | ProShare Advisors LLC | reduced | -11.57 | -118,866 | 98,925 | -% |
2023-05-22 | AMERIPRISE FINANCIAL INC | reduced | -0.78 | -560,613 | 581,387 | -% |
2023-05-18 | NEW YORK STATE COMMON RETIREMENT FUND | reduced | -42.54 | -519,000 | 217,000 | -% |
2023-05-18 | JPMORGAN CHASE & CO | added | 0.35 | -3,264,000 | 3,472,000 | -% |
2023-05-16 | JANE STREET GROUP, LLC | new | - | 1,435,660 | 1,435,660 | -% |
2023-05-16 | PERCEPTIVE ADVISORS LLC | sold off | -100 | -5,374,510 | - | -% |
2023-05-16 | SUSQUEHANNA INTERNATIONAL GROUP, LLP | new | - | 230,371 | 230,371 | -% |
2023-05-15 | Weiss Multi-Strategy Advisers LLC | new | - | 477,000 | 477,000 | 0.01% |
2023-05-15 | SAMLYN CAPITAL, LLC | new | - | 8,507,190 | 8,507,190 | 0.15% |
2023-05-15 | TWO SIGMA ADVISERS, LP | new | - | 327,645 | 327,645 | -% |
Date Filed | Name of Filer | Percent of Class | No. of Shares | Form Type | |
---|---|---|---|---|---|
Apr 10, 2023 | wellington management group llp | 11.05% | 7,372,601 | SC 13G/A | |
Mar 16, 2023 | biotechnology value fund l p | 2.7% | 1,794,881 | SC 13G | |
Feb 14, 2023 | rock springs capital management lp | 5.94% | 3,961,249 | SC 13G/A | |
Feb 14, 2023 | biotechnology value fund l p | 2.6% | 1,732,725 | SC 13G/A | |
Feb 13, 2023 | foresite capital fund iv, l.p. | 4.2% | 2,808,034 | SC 13G/A | |
Feb 06, 2023 | wellington management group llp | 8.22% | 5,484,013 | SC 13G/A | |
Jan 31, 2023 | blackrock inc. | 7.6% | 5,087,435 | SC 13G/A | |
Apr 25, 2022 | ra capital management, l.p. | 7.1% | 4,398,453 | SC 13G | |
Feb 15, 2022 | rock springs capital management lp | 6.31% | 3,861,347 | SC 13G/A | |
Feb 14, 2022 | venrock healthcare capital partners ii, l.p. | 7.5% | 4,563,962 | SC 13G |
Date Filed | Form Type | Document | |
---|---|---|---|
Jun 02, 2023 | 8-K | Current Report | |
Jun 01, 2023 | 8-K | Current Report | |
May 08, 2023 | 10-Q | Quarterly Report | |
May 08, 2023 | 8-K | Current Report | |
May 08, 2023 | S-8 | Employee Benefits Plan | |
Apr 20, 2023 | ARS | ARS | |
Apr 20, 2023 | DEF 14A | DEF 14A | |
Apr 20, 2023 | DEFA14A | DEFA14A | |
Apr 14, 2023 | 8-K | Current Report | |
Apr 10, 2023 | PRE 14A | PRE 14A |
Datesorted ascending | Name | Buy/Sell | $ Value | Avg. Price | # Shares | Title |
---|---|---|---|---|---|---|
2023-03-17 | Manion Douglas J. | bought | 49,532 | 7.8623 | 6,300 | pres and ceo |
2023-03-09 | Manion Douglas J. | bought | 50,277 | 7.735 | 6,500 | pres and ceo |
2023-03-03 | Monahan Joseph | sold | -202,615 | 12.6342 | -16,037 | chief scientific officer |
2023-03-03 | Balthaser Kevin | sold | -11,289 | 12.6281 | -894 | chief financial officer |
2023-03-03 | Walker Neal | sold | -382,070 | 12.6346 | -30,240 | - |
2023-03-02 | Walker Neal | acquired | - | - | 18,254 | - |
2023-03-02 | Balthaser Kevin | sold | -12,289 | 12.289 | -1,000 | chief financial officer |
2023-03-02 | Monahan Joseph | sold | -183,024 | 12.3665 | -14,800 | chief scientific officer |
2023-03-02 | Balthaser Kevin | acquired | - | - | 1,500 | chief financial officer |
2023-03-02 | Walker Neal | sold | -358,588 | 12.3651 | -29,000 | - |
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS - USD ($) $ in Thousands | 3 Months Ended | |
---|---|---|
Mar. 31, 2023 | Mar. 31, 2022 | |
Revenues: | ||
Total revenue | $ 2,528 | $ 1,453 |
Costs and expenses: | ||
Cost of revenue | 808 | 1,155 |
Research and development | 22,587 | 14,306 |
General and administrative | 8,790 | 6,099 |
Licensing | 1,061 | |
Revaluation of contingent consideration | (800) | (1,200) |
Total costs and expenses | 32,446 | 20,360 |
Loss from operations | (29,918) | (18,907) |
Other income, net | 1,758 | 118 |
Net loss | $ (28,160) | $ (18,789) |
Net loss per share, basic | $ (0.42) | $ (0.31) |
Net loss per share, diluted | $ (0.42) | $ (0.31) |
Weighted average common shares outstanding, basic | 66,872,778 | 61,431,026 |
Weighted average common shares outstanding, diluted | 66,872,778 | 61,431,026 |
Other comprehensive income (loss): | ||
Unrealized gain (loss) on marketable securities, net of tax of $0 | $ 543 | $ (748) |
Total other comprehensive income (loss) | 543 | (748) |
Comprehensive loss | (27,617) | (19,537) |
Contract research | ||
Revenues: | ||
Total revenue | 889 | 1,221 |
Licensing | ||
Revenues: | ||
Total revenue | $ 1,639 | 202 |
Other | ||
Revenues: | ||
Total revenue | $ 30 |
CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands | Mar. 31, 2023 | Dec. 31, 2022 |
---|---|---|
Current assets: | ||
Cash and cash equivalents | $ 44,722 | $ 45,277 |
Short-term marketable securities | 126,081 | 172,294 |
Accounts receivable, net | 686 | 484 |
Prepaid expenses and other current assets | 12,872 | 13,495 |
Total current assets | 184,361 | 231,550 |
Marketable securities | 33,602 | 12,242 |
Property and equipment, net | 1,513 | 1,099 |
Intangible assets | 6,954 | 6,973 |
Other assets | 3,275 | 2,732 |
Total assets | 229,705 | 254,596 |
Current liabilities: | ||
Accounts payable | 8,190 | 10,351 |
Accrued expenses | 7,263 | 8,701 |
Current portion of lease liabilities | 603 | 684 |
Discontinued operations | 2,202 | 2,202 |
Total current liabilities | 18,258 | 21,938 |
Other liabilities | 1,970 | 1,570 |
Contingent consideration | 32,300 | 33,100 |
Deferred tax liability | 367 | 367 |
Total liabilities | 52,895 | 56,975 |
Commitments and contingencies (Note 14) | ||
Stockholders' Equity: | ||
Preferred stock, $0.00001 par value; 10,000,000 shares authorized and no shares issued or outstanding at March 31, 2023 and December 31, 2022 | ||
Common stock, $0.00001 par value; 100,000,000 shares authorized at March 31, 2023 and December 31, 2022; 67,206,025 and 66,688,647 shares issued and outstanding at March 31, 2023 and December 31, 2022, respectively | 1 | 1 |
Additional paidin capital | 887,638 | 880,832 |
Accumulated other comprehensive loss | (354) | (897) |
Accumulated deficit | (710,475) | (682,315) |
Total stockholders' equity | 176,810 | 197,621 |
Total liabilities and stockholders' equity | $ 229,705 | $ 254,596 |